Drug Trial Radar · NCT04630067
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Nov 17, 2020
Primary completion
Sep 14, 2022
Study completion Sep 14, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).
Conditions
- Heart Failure
Interventions
AZD3427Drug
Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
PlaceboDrug
Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events and Serious Adverse EventsTime frame: Part A: Day 1 until Day 50 or Early termination visit (E/T); Part B: Day 1 until Day 78 or E/T
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Little Rock, Arkansas
Research Site
Glendale, California
Research Site
Daytona Beach, Florida
Research Site
Doral, Florida
Research Site
Hallandale, Florida
Research Site
Jacksonville, Florida
Research Site
Owensboro, Kentucky
Research Site
Brooklyn, Maryland
Research Site
Detroit, Michigan
Research Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.